Sera Prognostics, Inc. (SERA)

NGM – Real Time Price. Currency in USD

1.80

0.00 (0.00%)

At close: Jun 26, 2026, 4:00 PM EDT

1.80

0.00 (0.00%)

After-hours: Jun 26, 2026, 4:10 PM EDT

01.06.2026

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SALT LAKE CITY, June 1, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott has notified the Company of his intention to step down from its Board of Directors, effective June 4, 2026, and that he will not stand for re-election at the Company's upcoming Annual Meeting of Shareholders. Mr. Elliott has served on Sera's Board since March 2025, providing strategic guidance and leadership during a period of growth and development for the Company.

14.05.2026

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

07.05.2026

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

06.05.2026

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

Sera Prognostics, Inc. (SERA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago.

06.05.2026

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SALT LAKE CITY, May 6, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the first quarter ended March 31, 2026. Key First Quarter and Recent Highlights: Published Landmark PRIME Randomized Trial: Study in 5,018 women showing the PreTRM® test reduced early preterm births (–56%

22.04.2026

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

SALT LAKE CITY, April 22, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced it will report first quarter fiscal year 2026 financial results on Wednesday May 6, 2026, after the close of the market. The Company will host a corresponding conference call and live webcast to discuss operational highlights, financial results and key topics at 5:00 p.m.

31.03.2026

Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?

Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Videos

No Data

There is no data to display

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

SALT LAKE CITY, March 18, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key 2025 and Recent Highlights: Data Generation Published Landmark PRIME Study Demonstrating PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications: In January 2026, the PRIME Study, a randomized controlled trial of 5,018 women, was published in PREGNANCY, the peer-reviewed journal of the Society for Maternal-Fetal Medicine.

24.11.2025

Sera Announces Publication Acceptance for PRIME Study

The PRIME study, one of the largest studies on preterm birth, has been accepted for publication by a medical journal following abstract presentation earlier this year SALT LAKE CITY , Nov. 24, 2025 /PRNewswire/ -- Sera Prognostics, Inc. , The Pregnancy Company® (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the findings of the Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study were accepted for publication in a peer-reviewed journal. The PRIME study's abstract data was selected as a late-breaking abstract for podium presentation earlier this year at the Society for Maternal-Fetal Medicine's (SMFM) annual meeting.

Sera Prognostics, Inc. (SERA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sera Prognostics, Inc. (SERA)

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Sera Announces Publication Acceptance for PRIME Study

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Sera Announces Publication Acceptance for PRIME Study

Search stocks

Sera Prognostics, Inc. (SERA)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Sera Prognostics, Inc. (SERA)

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Sera Announces Publication Acceptance for PRIME Study

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

Sera Prognostics (SERA) Loses 27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Sera Prognostics, Inc. (SERA) Q1 2026 Earnings Call Transcript

Sera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue Estimates

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF FIRST QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON MAY 6, 2026

Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock?

Videos

No Data

Press releases

SERA PROGNOSTICS ANNOUNCES BOARD TRANSITION

SERA PROGNOSTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS

Sera Announces Publication Acceptance for PRIME Study